O
CTMX icon

OrbiMed’s CytomX Therapeutics CTMX Stock Holding History

OrbiMed’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,525,650
Closed -$15M – 117
2025
Q4 		$15M Sell
3,525,650
-4,935,850
-58% -$18.8M 0.31% 69
2025
Q3 		$27M Hold
8,461,500
– – 0.63% 45
2025
Q2 		$19.2M Buy
+8,461,500
New +$13.6M 0.48% 42
2024
Q2 		– Sell
-3,544,578
Closed -$7.73M – 120
2024
Q1 		$7.73M Buy
+3,544,578
New +$6.54M 0.14% 90
2022
Q3 		– Sell
-2,124,975
Closed -$3.89M – 135
2022
Q2 		$3.89M Hold
2,124,975
– – 0.07% 119
2022
Q1 		$5.67M Sell
2,124,975
-1,089,534
-34% -$4.18M 0.09% 118
2021
Q4 		$13.9M Buy
3,214,509
+1,392,641
+76% +$8.16M 0.18% 104
2021
Q3 		$9.27M Buy
1,821,868
+308,700
+20% +$1.65M 0.1% 131
2021
Q2 		$9.58M Buy
+1,513,168
New +$11.8M 0.1% 127

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed's CTMX Position: Q1 2026 in Review

OrbiMed sold out of CytomX Therapeutics (CTMX) in Q1 2026, closing a stake of 3,525,650 shares — an estimated $15M sold.

OrbiMed first reported a position in CTMX in Q2 2021 and held it in 9 quarters. The position peaked at $27M in Q3 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • OrbiMed reported no remaining CytomX Therapeutics position as of Q1 2026 after selling out during the quarter.
  • OrbiMed sold 3,525,650 CytomX Therapeutics shares in Q1 2026, an estimated $15M.
  • OrbiMed first reported a position in CytomX Therapeutics in Q2 2021 and held it in 9 quarters.
  • OrbiMed's CytomX Therapeutics position peaked at $27M in Q3 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.